Publicacións en colaboración con investigadores/as de Hospital Virgen de La Luz de Cuenca (28)

2024

  1. Characterizing Hepatitis Delta in Spain and the gaps in its management

    Gastroenterologia y Hepatologia

  2. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

  3. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  4. The prognostic value of blood cellular indices in pulmonary embolism

    American Journal of Hematology, Vol. 99, Núm. 9, pp. 1704-1711

2023

  1. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

    Thrombosis Update, Vol. 13

  2. Benefits of Paediatric to Adult Transition Programme in Inflammatory Bowel Disease: The BUTTERFLY Study of GETECCU and SEGHNP

    Journal of Clinical Medicine, Vol. 12, Núm. 14

  3. Effectiveness and Safety of Ustekinumab in Elderly Patients with Crohn's Disease: Real World Evidence From the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 17, Núm. 1, pp. 83-91

  4. Machine learning to predict major bleeding during anticoagulation for venous thromboembolism: possibilities and limitations

    British Journal of Haematology, Vol. 201, Núm. 5, pp. 971-981

  5. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

  6. Risk for recurrence of symptomatic upper-extremity deep vein thrombosis in patients without cancer: Analysis of three RIETE cohorts

    Vascular Medicine (United Kingdom), Vol. 28, Núm. 4, pp. 324-330

  7. Women in urology: What is their current situation in Spain?

    Actas Urologicas Espanolas, Vol. 47, Núm. 7, pp. 462-469

2022

  1. Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial

    Journal of Clinical Medicine, Vol. 11, Núm. 19

  2. Nationwide COVID-19-EII Study: Incidence, Environmental Risk Factors and Long-Term Follow-Up of Patients with Inflammatory Bowel Disease and COVID-19 of the ENEIDA Registry

    Journal of Clinical Medicine, Vol. 11, Núm. 2

  3. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)

    Journal of Clinical Medicine, Vol. 11, Núm. 24

2021

  1. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 11, pp. 1846-1851

  2. Erratum: Risk factors associated with adverse fetal outcomes in pregnancies affected by Coronavirus disease 2019 (COVID-19): A secondary analysis of the WAPM study on COVID-19 (Journal of Perinatal Medicine (2020) 48:9 (950-958) DOI: 10.1515/jpm-2020-0355)

    Journal of Perinatal Medicine

  3. Incidence, clinical characteristics, risk factors and outcomes of meningoencephalitis in patients with COVID-19

    European Journal of Clinical Microbiology and Infectious Diseases, Vol. 40, Núm. 8, pp. 1645-1656

  4. Management of acquired hemophilia A: results from the Spanish registry

    Blood Advances, Vol. 5, Núm. 19, pp. 3821-3829

  5. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection

    Ultrasound in Obstetrics and Gynecology, Vol. 57, Núm. 2, pp. 232-241

  6. Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42